Browse > Article

THE EFFECTS OF OVARIECTOMY ON TITANIUM IMPLANT OSSEOINTEGRATION IN RAT'S TIBIA  

Kim, Byung-Min (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
Sung, Iel-Yong (Dept. of Oral and Maxillofacial Surgery, College of Medicine, Ulsan University)
Park, Bong-Soo (Dept. of Oral Anatomy, College of Dentistry, Pusan National University)
Shin, Sang-Hoon (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
Kim, Jong-Ryoul (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.29, no.6, 2003 , pp. 397-406 More about this Journal
Abstract
The purpose of this study was to observe the titanium implant osseointegration in the osteoporosis-induced animal model. Seventy rats, 11 weeks of age, were divided into two groups : an ovariectomized group and a control group. Titanium screw implants(diameter, 2.0mm; length, 3.5mm) were placed into left tibias of 70 rats, 35 in the control group and 35 in the experimental group. The rats were sacrificed at different time interval (1, 2, 3, 4, 6, 8, and 12 weeks after implantation) for histopathologic observation, histomorphometric analysis and immunohistochemistry with fibronectin and CD34 antibody. The results obtained from this study were as follows: 1. Histopathologically findings, newly formed bone was seen at 3 weeks and became lamellar bone at 8 weeks, and mature trabecullar bone was seen at 12 weeks control group. In experimental group, thickness of regenerated bone increased till 8 weeks gradually and mature trabecullar bone was seen at 12 weeks. 2. By histomorphometric analysis, marrow bone density and contact ratio of marrow bone to implant decreased significantly from 8 to 12 weeks in experimental group compared to control group and also total bone to implant contact ratio decreased significantly from 8 to 12 weeks in experimental group. 3. Fibronectin immunoreactivity was strong at 3 weeks control group and reduced after 8weeks gradually. But it was continuously strong from 3 to 8 weeks in experimental group. 4. CD34 immunoreactivity was very strong in the newly formed osteoblasts from 3 to 8 weeks control group. But it reacted minimally later. While in experimental group, it reacted continuously strong from 3 to 12 weeks. The results of this study suggest that osteoporosis is not an absolute contraindication to dental implantation if sufficient period suggested after fixture installation till second stage surgery.
Keywords
Ovariectomy; Osteoporosis; Osseointegration;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cummings SR, Kelsey JL, Nevitt MC, et al: Epidermiology of osteoporosis and osteoporotic fracture. Epidermiol Rev 7:178, 1985.
2 Noda M : Transcriptional regulation of osteocalcin production by transforming growth factor-$\beta$ in rat ostoeblast-like cells. Endocrinology 124(2):612-617, 1988.   DOI   PUBMED   ScienceOn
3 Turner AS, Mallinckrodt CH, Alvis MR, Bryant HU: Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes. Bone 17(4): 421-427, 1995.   DOI   ScienceOn
4 Nordahl J, Mengarelli-Widholm S, Hultenby K, Reinholt FP: Ultrastru ctural immunolocalization of fibronectin in epiphyseal and metaphyseal bone of young rats. Calcif Tissue Int 57:442-449, 1995.   DOI   ScienceOn
5 Moursi AM, Damsky CH, Lull JC, Zimmerman D, Doty SB, Aota S-I, Globus RK: Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109:1369-1380, 1996.   PUBMED
6 Kribbs PJ, Chesnut CH III, Ott SM, Kilcoyne RF: Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 62:703-7, 1989.   DOI   ScienceOn
7 Steiger P, Cummings SR, Black DM, et al: Age-related decrements in bone mineral density in women over 65. J Bone Miner Res 7:625, 1992.
8 Martin RB, Daul HA, Bargar WL, et al: Effects of estrogen deficiency on the growth tissue into porous titanium implants. J Bone Joint Surg Am 70: 540, 1988
9 Dao TT, Anderson JD, Zarb GA: Is osteoporosis a risk factor for oss eointegration of dental implants?: Int J Oral Maxillofac Implants 8:13 7, 1993.
10 Lark MW, Stroup GB, Hwang SM, et al : Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J Pharmacol Exp Ther 291(2):612-7, 1999.   PUBMED
11 Kalu DN : The ovariectomized rat model of postmenopausal bone l oss. Bone and Mineral 15:175-192,1991.
12 Pei X: Who is hematopoietic stem cell: CD34+ or CD34-? Int J Hema tol 70: 213-215, 1999.
13 Holyoake TL, Alcorn MJ: CD34+ positive haemopoietic cells: biology and clinical applications. Blood Rev 8:113-124, 1994.   DOI   ScienceOn
14 von Wowern N, Storm TL, Olgaard K: Bone mineral content by absorptionmetry of the mandible compared with that of the forearm an d lumbar spine. Calcif Tissue Int 42:157, 1988
15 Ernster VL, Huggins GR, Hulka BS, Kelsey JL, Schottenfeld F: Benefits and risks of menopausal estrogen and/or rogestin hormone use. Prev Med 17: 201-223, 1988.   DOI   ScienceOn
16 Jeffcoat MK, Chesnut CH: Systemic osteoporosis and oral bone loss: evidence shows increased risk factors: J Am Dent Assoc vol.12 4:49-56, 199.
17 Mangaroo J, Glasser JH, Roht LH, et al: Prevalence of bone dimineralization in the United States, Bone 6:135, 1985.
18 Krook L, Whalen JP, Lesser GV, et al: Human periodontal disease and osteoporosis. Cornell Vet 62:371, 1972
19 Wood HB, May G, Healy L, Enver T, Morriss-Kay GM: CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoies is. Blood 15: 2300-2311, 1997.
20 Johnson RB, Gilbert JA, Cooper RC, et al: Alveolar bone loss one year following ovariectomy in sheep. J Periodontol 68(9):864-871, 1997.   DOI   PUBMED   ScienceOn